Monk BJ, et al. - In this prospective multicenter phase 2 trial conducted with patients with platinum-resistant recurrent ovarian, tubal or peritoneal cancer, researchers assessed the frequency of objective tumor responses (ORR) to determine the activity of IV elesclomol plus weekly paclitaxel, given that elesclomol has been suggested to increase oxidative stress and enhance sensitivity to cytotoxic agents in preclinical data. Of 58 patients enrolled, of whom 2 received no study treatment and were inevaluable, 11 patients responded to treatment and complete response was seen in one patient. The estimated median progression-free survival was 3.6?months and overall survival was 13.3?months. Overall, the combination of IV elesclomol plus weekly paclitaxel showed good tolerability, but due to the proportion responding, is not worthy of further inquiry.